Cargando…
Therapeutic vaccines in HBV: lessons from HCV
Currently, millions of people infected with hepatitis B virus (HBV) are committed to decades of treatment with anti-viral therapy to control viral replication. However, new tools for immunotherapy that include both viral vectors and molecular checkpoint inhibitors are now available. This has led to...
Autor principal: | Barnes, Eleanor |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4305103/ https://www.ncbi.nlm.nih.gov/pubmed/25573348 http://dx.doi.org/10.1007/s00430-014-0376-8 |
Ejemplares similares
-
HBV and HCV Therapy
por: Lampertico, Pietro, et al.
Publicado: (2009) -
Ever closer to a prophylactic vaccine for HCV
por: Swadling, Leo, et al.
Publicado: (2013) -
Impact of HCV viremia on HBV biomarkers in patients coinfected with HBV and HCV
por: Tseng, Chih-Wei, et al.
Publicado: (2022) -
Hurdles to the Development of Effective HBV Immunotherapies and HCV Vaccines
por: Torres-Cornejo, Almudena, et al.
Publicado: (2017) -
Circulating Interferon-λ3, Responsiveness to HBV Vaccination, and HBV/HCV Infections in Haemodialysis Patients
por: Grzegorzewska, Alicja E., et al.
Publicado: (2017)